GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sangamo Therapeutics Inc (NAS:SGMO) » Definitions » FCF Yield %

Sangamo Therapeutics (Sangamo Therapeutics) FCF Yield % : -220.61 (As of May. 02, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangamo Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Sangamo Therapeutics's Trailing 12-Month Free Cash Flow is $-246.0 Mil, and Market Cap is $111.5 Mil. Therefore, Sangamo Therapeutics's FCF Yield % for today is -220.61%.

The historical rank and industry rank for Sangamo Therapeutics's FCF Yield % or its related term are showing as below:

SGMO' s FCF Yield % Range Over the Past 10 Years
Min: -488.84   Med: -5.34   Max: 10.43
Current: -220.61


During the past 13 years, the highest FCF Yield % of Sangamo Therapeutics was 10.43%. The lowest was -488.84%. And the median was -5.34%.

SGMO's FCF Yield % is ranked worse than
92.28% of 1555 companies
in the Biotechnology industry
Industry Median: -14.52 vs SGMO: -220.61

Sangamo Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -2,605.73%.


Sangamo Therapeutics FCF Yield % Historical Data

The historical data trend for Sangamo Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangamo Therapeutics FCF Yield % Chart

Sangamo Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.01 7.00 -23.44 -46.55 -254.18

Sangamo Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.28 -101.22 -115.12 -188.23 -219.92

Competitive Comparison of Sangamo Therapeutics's FCF Yield %

For the Biotechnology subindustry, Sangamo Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangamo Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's FCF Yield % falls into.



Sangamo Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Sangamo Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-245.997 / 96.7802022
=-254.18%

Sangamo Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-53.209 * 4 / 96.7802022
=-219.92%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sangamo Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Sangamo Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangamo Therapeutics (Sangamo Therapeutics) Business Description

Traded in Other Exchanges
Address
7000 Marina Boulevard, Brisbane, CA, USA, 94005
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.
Executives
Biogen Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Beers Courtney director C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
Margaret A Horn director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Nathalie Dubois-stringfellow officer: SVP-Chief Development Officer C/O SANGAMO THERAPEUTICS, INC., 7000 MARINA BOULEVARD, BRISBANE CA 94005
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
H Stewart Parker director
Biogen Ma Inc. 10 percent owner 225 BINNEY STREET, CAMBRIDGE MA 02142
Scott B. Willoughby officer: SVP, Gen. Counsel & Secretary 7000 MARINA BLVD, BRISBANE CA 94005
Gary Loeb officer: EVP & General Counsel 5885 HOLLIS ST., SUITE 100, EMERYVILLE CA 94608
Jason D. Fontenot officer: SVP, Chief Scientific Officer 7000 MARINA BLVD, BRISBANE CA 94005
Robert J. Schott officer: SVP, Head of Development 7000 MARINA BLVD, BRISBANE CA 94005
Rolf Andrew Ramelmeier officer: EVP, Technical Operations 7000 MARINA BLVD, BRISBANE CA 94005
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Kenneth J. Hillan director C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
David Mark Mcclung officer: EVP Chief Business Officer 7000 MARINA BLVD, BRISBANE CA 94005

Sangamo Therapeutics (Sangamo Therapeutics) Headlines

From GuruFocus